Plus Therapeutics, Inc. (NASDAQ:PSTV) Stock Has Average Target Price of $51.75 According to Brokerages

by · The Markets Daily

Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) has received an average rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $51.75.

Several research firms have recently commented on PSTV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Monday, June 8th.

View Our Latest Stock Analysis on Plus Therapeutics

Plus Therapeutics Stock Down 3.9%

Plus Therapeutics stock opened at $1.95 on Tuesday. The stock has a 50-day moving average price of $3.14 and a 200 day moving average price of $4.59. The company has a market capitalization of $13.42 million, a price-to-earnings ratio of -0.85 and a beta of 1.40. Plus Therapeutics has a 52 week low of $2.90 and a 52 week high of $23.42.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.43). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The business had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.11 million. Research analysts anticipate that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned about 0.37% of Plus Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive agents directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposome, also known as 186RNL or RNL. The treatment uses nanoliposomes to encapsulate the radioisotope rhenium-186 and is being evaluated for cancers affecting the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.

Featured Stories